The Food and Drug Administration approved Gazyva, the anti CD20 antibody obinutuzumab sold by Roche Genentech, on November 13 to induce remission of proteinuria in adults with primary membranous nephropathy who are at risk of disease progression. The agency states plainly that this is the first drug approved specifically for the condition.
Primary membranous nephropathy is a rare disease in which the immune system attacks the glomeruli, the filtering units of the kidney, so that large amounts of protein leak into the urine. Patients can develop high cholesterol, high blood pressure, severe swelling and kidney failure. Treatment until now has relied on medicines used off label, including tacrolimus and rituximab.
The approval rests on MAJESTY, a Phase 3 randomised open label study in 142 adults, run over a main period of 104 weeks. Complete remission of proteinuria, defined as a urine protein creatinine ratio of no more than 0.3 grams per gram with stable kidney filtration and no rescue therapy, treatment failure or early discontinuation, was achieved by 36 percent of patients on Gazyva against 6 percent on tacrolimus. HCPLive reports the adjusted difference as 31 percentage points, with a p value below 0.001. The trial did not compare Gazyva directly with rituximab, the off label antibody many kidney guidelines prefer, and that gap will shape how specialists place the drug.
Gazyva received Breakthrough Therapy, Orphan Drug and Priority Review designations for this indication. Its label carries boxed warnings for hepatitis B virus reactivation and for progressive multifocal leukoencephalopathy, a rare and serious brain infection. The most common side effects in the study were infusion related reactions and upper respiratory tract infection. Gazyva was already approved for certain cancers, active lupus nephritis and childhood onset idiopathic nephrotic syndrome, and the European CHMP separately backed its lupus use this month, so the franchise is broadening well beyond oncology.